Increasing of FKBP9 can predict poor prognosis in patients with prostate cancer

• Published in: Pathology, research and practice research and practice, 2020-01, Vol.216 (1), p.152732-152732, Article 152732
• Main Authors: Jiang, Fu-neng, Dai, Li-jun, Yang, Sheng-bang, Wu, Yong-ding, Liang, Yu-xiang, Yin, Xiao-li, Zou, Cui-yun, Zhong, Wei-de
• Format: Article
• Language: English
• Subjects: FKBP9; Prognosis; Prostate cancer
• ISSN: 0344-0338; 1618-0631
• DOI: 10.1016/j.prp.2019.152732

FK506 binding protein 9 (FKBP9) has been reported and identified for a long time, but its relationship with cancer is rarely studied. For example, the role of FK506 binding protein 9 in prostate cancer (PCa) is still unclear. Therefore, we decided to detect the expression level of FKBP9 in PCa and explore its clinical significance. The expression level of FKBP9 protein was detected by immunohistochemistry. In addition, it was demonstrated by high-throughput sequencing of mRNA levels in the TCGA (cancer genome atlas) dataset of 499 patients. Kaplan-meier analysis and Cox proportional hazard regression model were used to evaluate the relationship between FKBP9 expression and survival in prostate cancer patients. The expression of FKBP9 was localized in the cytoplasm, which in normal prostate tissues was obviously lower than that in PCa tissues (P = 0.001). High expression of FKBP9 was related with lymph node metastasis (P = 0.022) and distant metastasis (P = 0.028). Kaplan-Meier survival analysis revealed that the BCR-free survival of PCa patients with high FKBP9 level was significantly shortened (P=0.041). FKBP9 may be a cancer promoter that enhances PCa progression, and the level of FKBP9 may be used as an independent precursor of PCa patients.